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ABSTRACT
Introduction: Fragile X syndrome (FXS) is the leading
cause of inherited intellectual and developmental
disability. Policy development relating to carrier
screening programmes for FXS requires input from
large studies examining not only test uptake but also
psychosocial aspects. This study will compare carrier
screening in pregnant and non-pregnant populations,
examining informed decision-making, psychosocial
issues and health economics.
Methods and Analysis: Pregnant and non-pregnant
women are being recruited from general practices and
obstetric services. Women receive study information
either in person or through clinic mail outs. Women
are provided pretest counselling by a genetic
counsellor and make a decision about testing in their
own time. Data are being collected from two
questionnaires: one completed at the time of making
the decision about testing and the second 1 month
later. Additional data are gathered through qualitative
interviews conducted at several time points with a
subset of participating women, including all women
with a positive test result, and with staff from recruiting
clinics. A minimum sample size of 500 women/group
has been calculated to give us 88% power to detect a
10% difference in test uptake and 87% power to detect
a 10% difference in informed choice between the
pregnant and non-pregnant groups. Questionnaire
data will be analysed using descriptive statistics and
multivariate logistic regression models. Interview
data will be thematically analysed. Willingness-to-pay
and cost effectiveness analyses will also be performed.
Recruitment started in July 2009 and data collection
will be completed by December 2013.
Ethics and Dissemination: Ethics approval has
been granted by the Universities of Melbourne and
Western Australia and by recruiting clinics, where
required. Results will be reported in peer-reviewed
publications, conference presentations and through a
website http://www.fragilexscreening.net.au. The
results of this study will make a significant contribution
to discussions about the wider introduction of
population carrier screening for FXS.
ARTICLE SUMMARY
Article focus
▪ This article is a protocol of a study that involves
offering fragile X syndrome carrier screening to
pregnant and non-pregnant women in the
general population. We are undertaking a pro-
gramme evaluation approach using mixed
methods to collect data about informed decision-
making and predictors of test uptake, with a
focus on psychosocial measures. We are also
undertaking an economic appraisal.
Key messages
▪ Carrier screening for fragile X syndrome is the
subject of debate because of concerns around
education and counselling for this complex con-
dition and the potential for psychosocial harms.
▪ This study will inform policy and practice in the
area of population carrier screening by examin-
ing psychosocial aspects of screening, including
informed decision-making; models of screening,
through antenatal care or other access points
and health economics of carrier screening for
fragile X syndrome.
Strengths and limitations of this study
▪ This study seeks to recruit 1000 women in total.
This large sample size will give us sufficient
power to address the aims of the study.
▪ Collecting quantitative and qualitative data will
provide a more in-depth picture of screening for
fragile X syndrome.
▪ A limitation of the study is that the data on
models of screening may not be applicable to
other countries that have different healthcare
systems.
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INTRODUCTION
Population-based screening programmes are available
for a number of genetic conditions in the newborn, pre-
natal and preconception settings. Several guidelines
based on speciﬁc criteria exist to help assess which
genetic conditions are suitable for population screen-
ing.1 2 Fragile X syndrome (FXS) is an X linked condi-
tion which meets many of the criteria for population
screening, as discussed in Hill et al3 However, in many
countries, it is still not routine practice to offer carrier
screening for FXS. This is because of concerns about
the challenges of screening for this complex condition,
including the need for genetic counselling and educa-
tion and the potential psychosocial and other impacts of
a positive result, discussed further in Finucane et al.4
FXS is the most commonly inherited cause of intellectual
and developmental disability. Virtually all FXS is caused by
an expanded CGG trinucleotide repeat in the 5′ untrans-
lated region of the FMR1 gene, which leads to hypermethy-
lation and silencing of the gene.5–9 Currently, the normal
range of repeats is deﬁned as 6–44, with 45–54 repeats
being considered an intermediate ‘grey zone’ allele (GZ),
55–200 a premutation (PM) and >200 repeats a full muta-
tion (FM).10 11 The repeats in the GZ, PM and FM ranges
can expand when passed from mother to child, although
not usually from father to child.8 12 13
The FM is associated with intellectual disability, anxiety
and features of the autism spectrum and attention/
deﬁcit hyperactivity disorders.14 The clinical presentation
varies between individuals15 with men usually being more
severely affected than women. FXS is not curable but spe-
ciﬁc treatments exist, which may help a number of the
physical16–19 and behavioural symptoms.20 Although
there is currently no robust evidence to support speciﬁc
pharmacological treatments for people with FXS,21 a
number of new therapies are being trialled,22–25 which
may lead to improved treatments in the future.
In addition to the reproductive risk of having a child with
FXS, female FXS PM carriers also have personal health
risks: an increased risk of FX-associated primary ovarian
insufﬁciency (FXPOI) with a 20% risk of premature meno-
pause26–29; a higher incidence of mental health issues such
as anxiety and depression4; a risk of developing FX-
associated tremor/ataxia syndrome (FXTAS), a late onset
neurodegenerative condition, which is more common in
male PM carriers than in female PM carriers.29–31
The reported prevalence of FMR1 alleles varies. Three
large studies examining FMR1 in anonymous newborn
samples32–34 found frequencies of the FMR1 FM in males
of 1 in 263333 to 1 in 6209.34 The reported rates of PM in
females in four large studies12 34–36 ranged from 1 in
15412 in Israel to 1 in 54934 in Canada, with rates of 1 in
17835 and 1 in 20936 reported in the USA. Two large
studies reported GZ rates of 1 in 6636 to 1 in 85.34
A number of studies have investigated carrier screening
for FXS for women in the general population.12 37–46
Most of these studies focused on uptake of testing, FMR1
allele sizes and expansion rates, reproductive choices and
pregnancy outcomes. However, genetic population
screening guidelines1 emphasise the importance of
examining the psychosocial aspects of screening, includ-
ing informed decision-making. Only our pilot study43 47
and one other retrospective study39 have measured the
psychosocial impacts of screening for FXS and no studies
until now have examined informed decision-making.
This study aims to help us better understand the psy-
chosocial aspects of carrier screening for FXS and will
1. Compare informed decision-making by pregnant and
non-pregnant women offered carrier screening for FXS;
2. Compare uptake and predictors of uptake in preg-
nant and non-pregnant women offered carrier
screening for FXS;
3. Undertake an economic appraisal of FXS population
carrier screening.
Informed decision-making is complex and involves
many factors.48 One measure used in population carrier
screening for Down syndrome to estimate informed
decision-making is the multidimensional model of
informed choice (MMIC),49 which describes an
informed choice as a decision made with sufﬁcient
knowledge that is value consistent. Our study will not
only measure informed choice using MMIC but also
collect additional information on factors involved in
informed decision-making in the two study question-
naires and through qualitative interviews.
Our study will also provide information on when to
offer population carrier screening for FXS by comparing
screening in non-pregnant and pregnant women.
Population carrier screening guidelines recommend pre-
conception carrier screening,1 but such screening is
often embedded in antenatal care, as this provides a con-
venient (from the perspective of the service provider)
point of access, although it may be a more anxious time
for women. Research on informed decision-making in
prenatal screening, primarily for Down syndrome, has
shown that decisions about testing are often not
informed.50–53 Our study will be the ﬁrst to investigate
whether rates of informed choice and uptake differ
between pregnant and non-pregnant women.
We are testing two hypotheses
1. A lower proportion of pregnant women will make an
informed decision about carrier screening compared
with non-pregnant women;
2. Carrier screening for FXS will result in a higher
uptake of testing by pregnant women compared with
non-pregnant women.
The ﬁndings of this study will contribute valuable data
to inform debate on policy and approaches to popula-
tion carrier screening for FXS.
METHODS AND ANALYSIS
Key elements of study design
Study design
The development and implementation of an effective
carrier screening programme is a multistep process
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requiring a clear theoretical framework. We have devel-
oped a programme logic model (see ﬁgure 1) to investi-
gate FXS carrier screening incorporating ﬁve stages: (1)
negotiation and planning; (2) programme development;
(3) programme implementation; (4) short-term out-
comes and (5) long-term outcomes. The results of
our qualitative needs assessment and pilot study,
representing stages 1 and 2, have been published
previously.43 47 54 55
The current study covers stages 3 and 4 and uses a
mixed-methods approach to data collection to investi-
gate the short-term outcomes of implementing an FXS
carrier screening programme. Figure 2 provides an over-
view of the study design. Speciﬁcally, we will investigate
test uptake, informed decision-making, predictors of test
uptake, psychosocial outcomes (depression, anxiety,
stress, decisional conﬂict and decisional regret) and
health economic factors (willingness-to-pay, WTP).
The key elements of the study are that all women will
receive a purpose-made brochure and genetic counsel-
ling before making a decision about testing; the test is
optional, convenient and non-invasive and offered at no
charge to the participants. Genetic counselling and the
ﬁeld-tested brochure are included in the protocol, as
participants in our pilot study and needs assessment
indicated that having sufﬁcient information and the
chance to discuss it is important in making an informed
decision.43 54 Offering a test that can be performed at
home after sufﬁcient time for decision-making is import-
ant, as we found in our pilot study that having to return
to the clinic for an invasive test was identiﬁed as a
barrier to testing, although it did allow some time for
deliberation.43 Recruiting pregnant and non-pregnant
women will allow us to examine if there are any differ-
ences in test uptake, informed choice or psychosocial
measures between these groups. Our economic appraisal
Figure 1 Programme logic model to investigate fragile X syndrome carrier screening.
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will provide important information to guide policy on
offering carrier screening for FXS.
Settings
The study is being conducted in general practices,
public and private obstetric clinics and through private
obstetric ultrasound services in Melbourne, Victoria and
Perth, Western Australia.
General practice
In Australia, women may attend any general practice of
their choice and may choose to attend more than one
practice. General practitioners (GPs) are the gate-
keepers to access secondary and tertiary care services.
About 88% of the Australian population visit a GP at
least once a year.56 Most GP clinics also operate a
reminder system for the National Cervical Screening
Figure 2 Overview of study protocol. *See table 1 for details of measures included in questionnaires 1 and 2.
4 Martyn M, Anderson V, Archibald A, et al. BMJ Open 2013;3:e003660. doi:10.1136/bmjopen-2013-003660
Open Access
 group.bmj.com on February 2, 2014 - Published by bmjopen.bmj.comDownloaded from 
Programme, which offers women between the ages of 18
and 69 a cervical (Pap) smear test every 2 years. Thus,
most GP clinics have a mail-out system in place to send a
reminder letter to their female patients every 2 years.
This provides one approach to inviting non-pregnant
women into the study and could act as a future service
model for population carrier screening.
Obstetrics
A range of maternity care models exist in Australia, but
they can be broadly divided into private maternity care,
public hospital maternity care and shared local health
practitioner/public hospital maternity care. The ﬁrst
step in accessing maternity care is to attend a GP in
early pregnancy to obtain a referral to a private obstetri-
cian or public hospital. The timing of the ﬁrst appoint-
ment with the maternity care provider varies, but in the
public hospital system women are often not seen until
the second trimester of pregnancy. In 2009, the majority
(96.9%) of Australian women gave birth in hospitals and
of these, 69.9% (150 157 women) were in the public
system and 30.1% (64 771 women) were in the private
system.57
Obstetric ultrasound—first trimester combined screening
Provision of antenatal screening varies across Australia.
In Victoria50 and Western Australia,58 ﬁrst trimester com-
bined screening is available through private pathology
laboratories and private ultrasound clinics with some
rebate available from the government-funded Medicare
system, while second trimester screening is state funded.
GPs or private obstetricians refer women to the private
ultrasound clinic for a ﬁrst trimester nuchal fold thick-
ness scan. In Victoria, about 70% of pregnant women
have ﬁrst trimester combined screening (L Bonacquisto,
2013, personal communication) and therefore would be
expected to attend a private ultrasound practice. In add-
ition to offering testing at initial presentation in primary
care, linking FXS carrier screening to ﬁrst trimester
screening is another potential service model.
Participants
Enrolling women in the study
Women are eligible to enter the study if they are 18 or
over and either not pregnant or up to 12 weeks+6 days
pregnant at the time of recruitment. For non-pregnant
women, the upper age limit is 70, the age at which par-
ticipation in the National Cervical Screening
Programme ends. Women who are unable to speak, read
and write English are not eligible to enter the study.
Recruitment occurs in a number of different ways
according to the preferences of individual clinics.
Non-pregnant women are recruited from general prac-
tice clinics. Women are provided with information about
the study either personally (by a researcher, GP, practice
nurse or receptionist) or they receive the information
through the mail. Study information is not provided by
researchers to women who attend general practice
clinics and who are obviously ill. Pregnant women are
recruited from general practice, private ultrasound and
private or public obstetric and ultrasound clinics. In
general practice, women are provided with information
about the study by the GP when they attend their preg-
nancy conﬁrmation appointment. In private ultrasound
clinics, study information is provided by clinic reception
staff when women attend their 12-week scan. In private
and public obstetric clinics, women are sent the study
information in the mail prior to their ﬁrst appointment
or are given the information personally by an obstetri-
cian or midwife. Women who receive information about
the study are asked to complete an expression of interest
which is faxed to the research team, either indicating
why they do not wish to take part or providing their
contact details so they can be recruited by a researcher.
All recruitment is completed by the research team and
all women speak with a research genetic counsellor.
Enrolling clinics in the study
General practice clinics located across the metropolitan
areas of Melbourne and Perth are being targeted to try
and achieve a geographical spread and a broad repre-
sentation of different socioeconomic areas. General
practices with established shared-care programmes are
being identiﬁed using registered shared-care provider
lists. Professional networks and an in-house database of
GPs and obstetricians who have previously ordered pre-
natal carrier testing for FXS or cystic ﬁbrosis in Victoria
are also being used to identify practices that might be
interested in participating. We anticipate requiring ﬁve
general practices, ﬁve private obstetric clinics and one
obstetric ultrasound clinic to recruit the 1000 women
needed for the study.
Members of the project team provide academic detail-
ing to clinics involved in recruitment. Academic detail-
ing covers background information on FXS, the aims of
the project and what the study involves for participants.
It is emphasised that the aim of the study is not to test
as many women as possible, but rather to understand
what factors inﬂuence a woman’s decision to accept or
decline carrier testing for FXS. Clinics are provided with
project resources, including study brochures and expres-
sion of interest forms.
Australian GPs are primarily funded by a fee for the
service system and receive no government funding (per-
sonal or infrastructure) for involvement in research.
Private obstetricians and ultrasound clinics also receive
no government funding for involvement in research. All
clinics are offered a small amount of remuneration to
cover their costs of involvement in the study, depending
on the number of women recruited from their clinic.
Data collection
This research protocol will use mixed-methods data col-
lection that includes genetic testing uptake and out-
comes, questionnaires and interviews.
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Questionnaires
The questionnaires use validated and psychometrically
robust self-reported scales. Table 1 shows which scales are
used in questionnaire 1 (Q1), completed after making a
decision about carrier testing for FXS, and questionnaire
2 (Q2), completed 1 month after returning Q1.
Interviews
To provide in-depth data on participants’ experiences,
semi-structured qualitative interviews are conducted with
participants at a number of time-points (see table 2).
Interviews are conducted by two members of the
research team with genetic counselling and qualitative
research skills.
Data entry quality control
To ensure accuracy of the questionnaire data, every 20th
questionnaire entered is checked prior to analysis. The
rate of accuracy will be calculated as the number of
errors per number of data items entered. To ensure
rigour in the qualitative data analysis, transcripts will be
independently coded.
Testing
One of the aims of our study was to evaluate the perform-
ance of a new innovative assay speciﬁcally designed for
population screening for FXS.65 Therefore, for the ﬁrst
part of the study, we collected DNA from a saliva sample
(Oragene—DNA collection kit) and carried out the gold
standard two step diagnostic test8 66 in parallel with the
Table 1 Questionnaire measures and scales
Measure/scale Description Q1 Q2
Knowledge 10 item scale containing questions on fragile X syndrome (true/false/unsure). A
score of 7 or higher is classified as ‘good’ knowledge.55
√ √
Attitudes 5 item scale (0–4) used to assess a woman’s attitude to screening (beneficial/
harmful; important/unimportant, bad thing/good thing, pleasant/unpleasant,
worrying/not worrying). Dichotomous scale: women are classified as having a
positive (11–20) or a negative (0–10) attitude towards screening.49
√
Multidimensional model of
informed choice
Defines an informed choice as a decision made with ‘good’ knowledge, which
is consistent with a person’s values. Incorporates three dimensions:
knowledge, attitudes and uptake. Dichotomous scale: ‘informed choice’ or ‘not
informed choice’.49
√
Deliberation 6 item scale measuring the extent to which a decision is deliberated on a 5
point Likert scale (0 = strongly agree—4 = strongly disagree). Dichotomous
scale: responses below the midpoint (11 or under) classified as not deliberated
and those at or above the midpoint as deliberated.53
√
Decisional conflict scale 16 item scale measuring uncertainty about a course of action on a 5 point
Likert scale (0 = strongly agree—4 = strongly disagree). Mean scores are
reported with higher scores indicating higher decisional conflict. Scores range
from 0 to 100 with scores over 37.5 associated with decision delay or
uncertainty about implementation.60
√
Depression Anxiety Stress Scale
(DASS-21)
21 item scale divided into 3 subscales measuring depression, anxiety and
stress. Responses are classified into 5 categories: 1 (normal) to 5 (extremely
severe).61 62
√ √
State Trait Anxiety Index (STAI-6) 6 item scale measuring state anxiety. The maximum score is 80 with scores
31–49 considered as average and scores over 50 indicating elevated state
anxiety.59
√ √
Health belief 16 items measuring the importance of a range of factors which may influence
decision-making: perceived benefits; perceived susceptibility; perceived
severity and perceived barriers in a woman’s decision to accept or decline
testing for FXS.47 63
√
Decisional regret 5 item scale measuring distress or remorse after a healthcare decision using a
5 point Likert scale (0–4). Scores range from 0–100 with higher scores
indicating a higher level of regret.64
√
Willingness-to-pay (WTP) 2 questions (piloted) that address WTP and gross family income. Income
question has six income ranges with a tick box. WTP question has 11 item
income values with a tick box and sub-questions that address: (1) utility of test
(information only or information plus decision-making); and (2) who receives a
test result (recipient only or recipient plus shared with health share
professionals).
√
Sociodemographics Marital status, age, parity, reproductive life-stage, education, occupation,
postcode.
√
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innovative screening test. The routine FXS diagnostic test
may involve Southern blotting and therefore can take up
to 4 weeks.43 This is performed by the Victorian Clinical
Genetic Service laboratory. Reﬁnements to the innovative
screening assay67 mean that we are now able to collect
DNA from cheek brush samples and have results available
in 1 week. This screening assay, marketed by Asuragen, is
being performed by Healthscope Pathology.
All women who choose to have carrier testing are
given information about their result based on current
best practice. Women with a result in the normal range
receive a letter that includes an offer to speak to a
genetic counsellor at their local clinical service should
they require further information. Women with a test-
positive result (GZ, PM or FM) are telephoned and
offered face-to-face genetic counselling at their local
clinical genetics service. Genetic counselling for women
with test-positive results follows usual clinical practice.4 68
Any pregnant woman found to have a PM or FM is given
her result and, as part of genetic counselling, is offered
prenatal diagnostic testing of the fetus, due to the risk of
having a child with FXS. An important outcome of
receiving an FXS carrier result is that relatives can access
genetic testing, which may lead to identiﬁcation of other
carriers and/or the diagnosis of FXS-related disorders in
other family members. Genetic testing is discussed as
part of the genetic counselling process and family
members are offered genetic counselling and testing
where appropriate.
Outcomes
The primary outcomes for the study are test uptake and
informed choice. Study participants (denominator) are
deﬁned as the number of women recruited in the study
who do not actively withdraw at any point. Test uptake is
deﬁned as the number of women who accept testing
(numerator) divided by the number of study partici-
pants and will be reported as a percentage. Informed
choice will be reported as the percentage of women in
each group (pregnant and non-pregnant, tested and
untested) making an informed choice as measured
using MMIC.62 MMIC will be measured in Q1 at the
time closest to decision-making. Knowledge, a compo-
nent of MMIC, will be measured in Q1 and Q2 and
mean knowledge scores will be reported for each time
point.
The study will also examine predictors of test uptake.
These multivariate analyses will make use of sociodemo-
graphic, family history, health belief and psychosocial
items included in Q1.
Psychosocial factors will be examined as secondary
measures in this study, including anxiety, depression and
stress. These will be administered in both questionnaires
to allow them to be measured at the time of decision-
making and 1 month later. Decisional conﬂict will be
measured in Q1 and decisional regret in Q2.
State anxiety will be reported as the difference in the
mean STAI-6 item short form score of women in each
group (pregnant and non-pregnant, tested and
untested, normal result vs test positive). Depression,
anxiety and stress will be reported as the mean score of
women in each group. Decisional conﬂict and decisional
regret will be reported as mean scores.
In the WTP literature, there is keen interest in how
WTP dollar values for information may vary in accord-
ance with intended use, who receives the information
and capacity-to-pay. Our questions have been designed
to address these key issues. Accordingly, WTP data will
Table 2 Overview of interview schedule
Time-point Interview type Interview description Selection
After return of Q1,
before Q2 and
result sent (if
tested)
Decision-making
interviews
Knowledge, attitudes, factors
influencing decision-making, the
decision-making process, and
perspectives on decisions
Non-pregnant women only; mix of
tested and untested women
One month after
return of Q2
Programme evaluation
interviews (women)
Motivations for participating, factors
influencing decision-making,
experience of participating in the
study including genetic counselling,
reflections on decision and views on
screening
Mix of tested and untested women
from each clinic, including all women
with positive test results.
Sociodemographic data examined to
ensure that selected women are
representative of the overall sample
After completion of
recruitment at any
given clinic
Programme evaluation
interviews (clinic staff)
Attitudes to population carrier
screening for fragile X syndrome
(FXS), knowledge of FXS, reflections
on offering FXS carrier screening at
their clinic, and feedback on the
study
Mix of staff from each clinic involved in
recruitment
1 year after return
of Q2
1 year follow-up Motivations for screening,
interpretation of result, perceived
value of result, impact of result and
reflections on decision
All women with a test-positive result
(ie, GZ, PM or FM)
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be reported in a number of ways: (1) intended use
(‘information only’ and/or ‘decision-making—personal
or medical’); (2) by recipients of information (‘women
only’ or ‘women plus healthcare professionals’); (3) for
women in the trial as a whole and for each group (preg-
nant and non-pregnant, tested and untested, normal
result vs test positive); as mean dollar values together
with associated ranges around each mean to facilitate
sensitivity testing.
Sample size
In our pilot study, in which women were required to
return on a separate occasion to give a blood sample,
test uptake in non-pregnant women was 20%, although
50% indicated that they intended to be tested.43 Based
on the relevance to reproductive life-stage, we expect
test uptake in the pregnant group to be greater than in
the non-pregnant group. Our minimum sample size of
500 women/group will give us 88% power to detect a
difference of 10% in test uptake between groups (50%
vs 40% or 50% vs 60%). We have less information about
the likely percentage of women making an informed
choice. If the percentage is 50, with a minimum sample
size of 500 per group, an unadjusted analysis would have
87% power to detect a difference of 10% (ie, 50% vs
40% or 50% vs 60%) between groups. If the base rate is
greater than or less than 50%, we would have >87%
power to detect a difference of 10%. The study will
therefore be sufﬁciently powered to exclude anything
other than small percentage differences between
groups.
Proposed analysis
Descriptive statistics will be used to describe the sociode-
mographic, knowledge, attitudes and psychological char-
acteristics of the sample. To compare the uptake of
testing by pregnant and non-pregnant women, a multi-
variate logistic regression model with uptake as the
dependent variable, and sociodemographic variables
such as age, education and parity, together with preg-
nant/non-pregnant status and mode of invitation or
recruitment as the independent variables, will be esti-
mated. This will ensure that a difference in uptake is not
due to differences in socioeconomic composition of the
pregnant and non-pregnant samples. Robust SEs will be
estimated to take into account the possible effect of clus-
tering due to recruitment methods. ORs will be trans-
formed back to percentage differences.69 A similar
analysis will be performed to compare informed choice.
To investigate predictors of uptake of testing, a multivari-
ate logistic regression model will be estimated with inde-
pendent variables including: informed choice, attitudes,
number of children, prior awareness of FXS, psycho-
social variables, family history of intellectual disability,
age and education. Interactions between predictors and
pregnancy/non-pregnancy will be examined and, if
necessary, separate models will be estimated for preg-
nant and non-pregnant women.
Interviews are transcribed verbatim and NVivo V.10
(QSR International, Australia) is being used to manage
the data and facilitate coding. Coding is being carried
out by at least two independent researchers to provide
rigour of analysis. The decision-making interviews are
being examined using content and thematic analysis.
These interviews occur between the return of Q1 and
the issue of results (for tested women) and Q2. As such,
they involve only non-pregnant women, as we were con-
cerned that an interview at this time before receiving a
result or needing to delay sending out the result prior to
the interview could be distressing for pregnant women
at a time when they might be vulnerable. Data from the
post-Q2 interviews are being analysed using directed
content analysis.70 The coding framework has been
developed using data from the needs assessment phase
of the study.43 47 54 As little prior research has explored
the experiences of women identiﬁed as carrying GZ, PM
or FM alleles through population-based carrier screen-
ing or the experiences of staff in clinics offering popula-
tion carrier screening, the interviews will be analysed
thematically. This will involve an iterative process where
data are coded, compared, contrasted and reﬁned to
generate emergent themes71 using an approach we have
described previously.54
The economic analysis is matched to the stages of FXS
carrier screening described in our programme logic
model (ﬁgure 1). At this stage, the analysis is concerned
with examining stage 3 (programme implementation)
and stage 4 (short-term outcomes). Placing a dollar
value on the health and non-health outcomes of FXS
screening is complex. The immediate result of FXS
screening is information. That information might be
about a risk to a fetus the woman is carrying, implica-
tions for the woman’s future health or implications for
the woman’s future reproductive health and reproduct-
ive choices. It is for this reason that we have started with
WTP methods to explore the value that individuals place
on the information provided. The WTP data will be ana-
lysed in accordance with the intervention design and
policy issues set out above. The WTP data will also be
analysed to see if there is an association between the
dollar values and preparedness to undergo testing.
Similarly, to the extent feasible, the relationship between
sociodemographic variables and WTP will be analysed to
see if these variables impact on WTP.
Longer-term economic modelling using a surrogate is
planned for stage 5. We aim to go on to record the
actions that the women undertake as a result of their
test results and the incidence of births of babies with
FXS to women in the study, discussion of test results with
family and identiﬁcation of carriers/affected individuals
with cascade testing. This will facilitate full economic
appraisal using a range of methods, including discrete
choice experiments (DCE). DCE has applicability to this
ﬁeld because non-health outcomes and process attri-
butes are also important and DCE is a logical extension
to WTP for inclusion in stage 5.
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ETHICS AND DISSEMINATION
Ethics
A plain language statement is provided to all women
and to clinics and health professionals involved in
recruiting women for the study and a signed consent
form is obtained from all participants at the time of
recruitment.
Steering group and advisory committee
This study has a designated research team and an advis-
ory group. The advisory group includes representation
from the Victorian Department of Health, the Fragile X
Association of Australia and clinicians involved in the
study. This group meets annually. The research team
includes expertise in population health, genetics,
primary care, epidemiology, FXS, health economics,
pathology and psychology, with the full team meeting
quarterly.
Dissemination
This study will be the ﬁrst of its kind worldwide to address
informed decision-making in carrier screening for FXS
and to compare screening in pregnant and non-pregnant
women. It will inform the development of appropriate
clinical service models for offering FXS screening and
also provide important exploratory health economic
data. We expect to publish one main trial outcome paper
and a number of additional papers exploring aspects of
the data in more detail. We will also present our ﬁndings
at a number of international conferences. A report out-
lining the main ﬁndings of the study will also be made
available on the study website http://www.
fragilexscreening.net.au on completion. The ﬁndings of
this study will inform policy development about when
and how to offer population carrier screening for FXS.
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